You have 9 free searches left this month | for more free features.

multiple sclerosis, fingolimod, adult, FTY720, inflammatory disease, demyelination, auto-inflammatory disease, relapsing-remitting MS, CFTY720D2406

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Multiple Sclerosis Trial in Belgium, Germany, Italy (Fingolimod)

Completed
  • Multiple Sclerosis
  • Gent, Belgium
  • +3 more
Jan 21, 2021

Multiple Sclerosis Trial in Pavia (18F-florbetaben PET/CT)

Recruiting
  • Multiple Sclerosis
  • 18F-florbetaben PET/CT
  • Pavia, PV, Italy
    ICS Maugeri SpA SB IRCCS
Mar 23, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in Chisinau (IMCY-0141, Placebo, Dimethyl Fumarate)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Chisinau, Moldova, Republic of
    Republican Clinical Hospital, ARENSIA Exploratory Medicine
Jun 8, 2022

Multiple Sclerosis, Relapsing-Remitting, Caloric Restriction Trial in Pozzilli (Caloric restriction, Caloric restriction without

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Caloric Restriction
  • Caloric restriction
  • Caloric restriction without cow's milk and gluten
  • Pozzilli, IS, Italy
    Neuromed - Istituto Neurologico Mediterraneo Pozzilli
Jul 26, 2022

Relapsing Multiple Sclerosis (RMS) Trial in China (Fingolimod 0.5mg)

Recruiting
  • Relapsing Multiple Sclerosis (RMS)
  • Fingolimod 0.5mg
  • Beijing, Beijing, China
  • +12 more
Feb 3, 2022

Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection Trial in Houston (Fingolimod, Placebo)

Enrolling by invitation
  • Interstitial Fibrosis
  • +6 more
  • Houston, Texas
    Houston Methodist Research Institute
Jan 23, 2023

Back Pain Trial (Pilates Exercise, Mckenzie Exercise)

Not yet recruiting
  • Back Pain
  • Pilates Exercise
  • Mckenzie Exercise
  • (no location specified)
Jun 1, 2023

Multiple Sclerosis Trial in Cairo (Blood sample collection)

Recruiting
  • Multiple Sclerosis
  • Blood sample collection
  • Cairo, Egypt
    Nasser Institute for Research and Treatment
Feb 21, 2023

Relapsing Remitting Multiple Sclerosis Trial in Worldwide (Pleneva TM BGC20-0134, Placebo)

Terminated
  • Relapsing Remitting Multiple Sclerosis
  • Pleneva TM BGC20-0134
  • Placebo
  • Gent, Belgium
  • +34 more
Jun 2, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in United States (Early Aggressive Therapy or Traditional Therapy)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Early Aggressive Therapy or Traditional Therapy
  • Birmingham, Alabama
  • +51 more
Jan 23, 2023

Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic Trial in Winston-Salem (Fingolimod 0.5 mg, Placebo, Standard of

Recruiting
  • Intracerebral Hemorrhage
  • +4 more
  • Fingolimod 0.5 mg
  • +2 more
  • Winston-Salem, North Carolina
    Wake Forest University Health Sciences
Nov 28, 2022

Multiple Sclerosis (MS) Trial in Dallas (Alemtuzumab)

Completed
  • Multiple Sclerosis (MS)
  • Dallas, Texas
  • +1 more
Jan 24, 2022

Multiple Sclerosis Trial in Clermont-Ferrand (Methylprednisolone, Placebo, natalizumab (NTZ))

Recruiting
  • Multiple Sclerosis
  • Clermont-Ferrand, France
    CHU Clermont-Ferrand
Jan 5, 2023

Multiple Sclerosis Trial (Randomized clinical trial.)

Not yet recruiting
  • Multiple Sclerosis
  • Randomized clinical trial.
  • (no location specified)
Sep 26, 2022

Multiple Sclerosis Trial in Bratislava ("Tai-chi" - a special program for patients with multiple sclerosis - once a week

Completed
  • Multiple Sclerosis
  • "Tai-chi" - a special program for patients with multiple sclerosis - once a week training with a Tai Chi instructor lasting 90 minutes
  • Bratislava, Slovak Republic, Slovakia
    2nd Department of Neurology, Faculty of Medicine COMENIUS UNIVER
Jul 21, 2022

Multiple Sclerosis Trial in Brussels (Visual Evoked Potential (VEP), Somatosensory evoked potential (SSEP), Transcranial

Recruiting
  • Multiple Sclerosis
  • Visual Evoked Potential (VEP)
  • +5 more
  • Brussels, Belgium
    CHU Brugmann
Jul 4, 2023

MS Trial in Giza (strengthening ex with BFR training, strengthening ex)

Recruiting
  • MS
  • strengthening ex with BFR training
  • strengthening ex
  • Giza, Egypt
    Faculty of physical therapy
Nov 16, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in Switzerland (serum Neurofilament Filament Light chain (sNfL) monitoring)

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • serum Neurofilament Filament Light chain (sNfL) monitoring
  • Basel, Basel Stadt, Switzerland
  • +7 more
Oct 17, 2023

Multiple Sclerosis, Relapsing-Remitting Trial in Porto Alegre (Cladribine 10 mg oral tablet)

Active, not recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Cladribine 10 mg oral tablet
  • Porto Alegre, RS, Brazil
    Pontifical Catholic University of Rio Grande do Sul
Jun 5, 2023

Neurodegeneration in Multiple Sclerosis -Preclinical Study

Not yet recruiting
  • Relapsing-Remitting Multiple Sclerosis (RRMS)
  • +2 more
  • Peripheral blood withdrawal
  • Pozzilli, Isernia, Italy
  • +2 more
Feb 15, 2022

Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (Ocrelizumab, Ocrelizumab Placebo, Fingolimod)

Recruiting
  • Relapsing-Remitting Multiple Sclerosis
  • La Jolla, California
  • +66 more
Jan 27, 2023

Intracerebral Hemorrhage Trial (Fingolimod)

Not yet recruiting
  • Intracerebral Hemorrhage
  • (no location specified)
Oct 17, 2023

Relapsing Multiple Sclerosis Trial in United States (Fingolimod)

Completed
  • Relapsing Multiple Sclerosis
  • Birmingham, Alabama
  • +65 more
Oct 6, 2021

Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination Trial (Tysabri Injectable Product, Placebo)

Recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome of Demyelination
  • Tysabri Injectable Product
  • Placebo
  • London, United Kingdom
    Royal London Hospital
Jan 25, 2023

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Saint Louis (Cladribine)

Recruiting
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Saint Louis, Missouri
  • +4 more
Jan 4, 2023